NEW YORK (GenomeWeb News) – Biomarker technology developer ApoCell has received an investment from Boston-based equity investor Summit Partners, which supports life sciences companies.

The amount of the investment was not disclosed.

ApoCell, which spun out from the University of Texas MD Anderson Cancer Center in 2005 and operates out of Houston, will use the funds to continue developing its technology platforms aimed at using biomarker signatures in oncology, diabetes, molecular diagnostics, and drug development.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.